Cargando…

Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole

Pharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in children in all stages, but it is controversial in chronically infected adults. We report the pharmacokinetics and pharmacodynamics in six adult patients with Chagas disease treated with the new BNZ formulation (ABAR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernández, Marisa Liliana, Marson, Maria Elena, Ramirez, Juan Carlos, Mastrantonio, Guido, Schijman, Alejandro Gabriel, Altcheh, Jaime, Riarte, Adelina Rosa, Bournissen, Facundo García
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Instituto Oswaldo Cruz, Ministério da Saúde 2016
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804505/ https://www.ncbi.nlm.nih.gov/pubmed/26982179 http://dx.doi.org/10.1590/0074-02760150401

Ejemplares similares

Population Pharmacokinetic Study of Benznidazole in Pediatric Chagas Disease Suggests Efficacy despite Lower Plasma Concentrations than in Adults
por: Altcheh, Jaime, et al.
Publicado: (2014)

Population pharmacokinetics of benznidazole in neonates, infants and children using a new pediatric formulation
por: Altcheh, Jaime, et al.
Publicado: (2023)

Benznidazole Treatment of Chagasic Encephalitis in Pregnant Woman with AIDS
por: Bisio, Margarita, et al.
Publicado: (2013)

Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease
por: Moroni, Samanta, et al.
Publicado: (2019)

Validation of Apolipoprotein A-1 and Fibronectin Fragments as Markers of Parasitological Cure for Congenital Chagas Disease in Children Treated With Benznidazole
por: Ruiz-Lancheros, Elizabeth, et al.
Publicado: (2018)

Longitudinal follow up of serological response in children treated for Chagas disease
por: Moscatelli, Guillermo, et al.
Publicado: (2019)

Miltefosine and Benznidazole Combination Improve Anti-Trypanosoma cruzi In Vitro and In Vivo Efficacy
por: Gulin, Julián Ernesto Nicolás, et al.
Publicado: (2022)

Prevention of congenital Chagas through treatment of girls and women of childbearing age
por: Moscatelli, Guillermo, et al.
Publicado: (2015)

Dried Blood Spot Technique-Based Liquid Chromatography-Tandem Mass Spectrometry Method as a Simple Alternative for Benznidazole Pharmacokinetic Assessment
por: Galindo Bedor, Danilo César, et al.
Publicado: (2018)

Biopharmaceutical Characteristics of Nifurtimox Tablets for Age‐ and Body Weight‐Adjusted Dosing in Patients With Chagas Disease
por: Stass, Heino, et al.
Publicado: (2020)

Serological based monitoring of a cohort of patients with chronic Chagas disease treated with benznidazole in a highly endemic area of northern Argentina
por: Niborski, Leticia L, et al.
Publicado: (2016)

Population pharmacokinetic modeling of benznidazole in Brazilian patients with chronic Chagas disease
por: Frade, Virgínia Paula, et al.
Publicado: (2022)

Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: A systematic review and meta-analysis
por: Ciapponi, Agustín, et al.
Publicado: (2020)

Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease
por: Rial, Marcela S., et al.
Publicado: (2017)

Preclinical pharmacokinetics of benznidazole.
por: Workman, P., et al.
Publicado: (1984)

Long-term cardiology outcomes in children after early treatment for Chagas disease, an observational study
por: González, Nicolás Leonel, et al.
Publicado: (2022)

Accurate Real-Time PCR Strategy for Monitoring Bloodstream Parasitic Loads in Chagas Disease Patients
por: Duffy, Tomas, et al.
Publicado: (2009)

Urban Chagas disease in children and women in primary care centres in Buenos Aires, Argentina
por: Moscatelli, Guillermo, et al.
Publicado: (2015)

Hepatic changes by benznidazole in a specific treatment for Chagas disease
por: Pavan, Tycha Bianca Sabaini, et al.
Publicado: (2018)

Access to benznidazole for Chagas disease in the United States—Cautious optimism?
por: Alpern, Jonathan D., et al.
Publicado: (2017)

Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas’ disease
por: Jackson, Yves, et al.
Publicado: (2020)

Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
por: Rolon, Miriam, et al.
Publicado: (2022)

From Benznidazole to New Drugs: Nanotechnology Contribution in Chagas Disease
por: Gomes, Daniele Cavalcante, et al.
Publicado: (2023)

Tolerance and Adherence of Patients with Chronic Chagas Disease Treated with Benznidazole
por: Vázquez, Cristina, et al.
Publicado: (2023)

Quality of Reporting and Adherence to ARRIVE Guidelines in Animal Studies for Chagas Disease Preclinical Drug Research: A Systematic Review
por: Gulin, Julián Ernesto Nicolás, et al.
Publicado: (2015)

Optimization and biological validation of an in vitro assay using the transfected Dm28c/pLacZ Trypanosoma cruzi strain
por: Gulin, Julián Ernesto Nicolás, et al.
Publicado: (2021)

The fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole
por: Robello, Carlos, et al.
Publicado: (2019)

Benznidazole, itraconazole and their combination in the treatment of acute experimental Chagas disease in dogs
por: Cunha, Eleonora Lima Alves, et al.
Publicado: (2019)

Congenital Chagas disease: Updated recommendations for prevention, diagnosis, treatment, and follow-up of newborns and siblings, girls, women of childbearing age, and pregnant women
por: Carlier, Yves, et al.
Publicado: (2019)

Benznidazole and Posaconazole in Experimental Chagas Disease: Positive Interaction in Concomitant and Sequential Treatments
por: Diniz, Lívia de Figueiredo, et al.
Publicado: (2013)

Evaluation of Parasiticide Treatment with Benznidazol in the Electrocardiographic, Clinical, and Serological Evolution of Chagas Disease
por: Fragata-Filho, Abilio Augusto, et al.
Publicado: (2016)

Benznidazole Use among Patients with Chronic Chagas' Cardiomyopathy in an Endemic Region of Brazil
por: Ferreira, Ariela Mota, et al.
Publicado: (2016)

Correction: The fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole
por: Robello, Carlos, et al.
Publicado: (2019)

Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole
por: Yoshioka, Kota, et al.
Publicado: (2020)

Characterization of adverse reactions to benznidazole in patients with Chagas disease in the Federal District, Brazil
por: Gontijo, Maria Katarine Costa Lucas, et al.
Publicado: (2020)

HIV and Chagas Disease Coinfection, a Tractable Disease?
por: Guidetto, Betiana, et al.
Publicado: (2019)

Efficacy of the Benznidazole+Posaconazole combination therapy in parasitemia reduction: An experimental murine model of acute Chagas
por: Echeverría, Luis Eduardo, et al.
Publicado: (2020)

Ruthenium Complex with Benznidazole and Nitric Oxide as a New Candidate for the Treatment of Chagas Disease
por: Sesti-Costa, Renata, et al.
Publicado: (2014)

Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment
por: Aguilera, Elena, et al.
Publicado: (2018)

Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study
por: Cardoso, Clareci Silva, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9rgg94570ari0efqlodqibhkka